Table 1 Patient characteristics and cancer treatment at baseline and extended follow-up

Age at baseline

52.4 ± 8.8

51.7 ± 8.0

51.6 ± 8.5

53.5 ± 9.8

0.76

Laterality (right vs left-sided)

24 (46%)

7 (47%)

6 (38%)

11 (52%)

0.67

Stage

0.50

 1

20 (38%)

8 (53%)

7 (44%)

5 (24%)

 2

14 (27%)

3 (20%)

4 (25%)

7 (33%)

 3

18 (35%)

4 (27%)

5 (31%)

9 (43%)

ER or PR positive

40 (77%)

13 (87%)

13 (81%)

14 (67%)

0.35

Coronary artery disease

0 (0%)

0 (0%)

0 (0%)

0 (0%)

Arrhythmia

0 (0%)

0 (0%)

0 (0%)

0 (0%)

Peripheral vascular disease

1 (2%)

0 (0%)

0 (0%)

1 (5%)

0.999

Diabetes type 2

3 (6%)

0 (0%)

1 (6%)

2 (10%)

0.77

Dyslipidemia

2 (4%)

0 (0%)

1 (6%)

1 (5%)

0.999

Hypertension

2 (4%)

1 (7%)

1 (6%)

0 (0%)

0.51

Family history of premature cardiovascular disease

0.37

 No

46 (88%)

15 (100%)

14 (88%)

17 (81%)

 Yes

4 (8%)

0 (0%)

2 (13%)

2 (10%)

 Unknown/adopted

2 (4%)

0 (0%)

0 (0%)

2 (10%)

Alcohol use

0.78

 None

13 (25%)

4 (27%)

4 (25%)

5 (24%)

 <1/day

37 (71%)

11 (73%)

12 (75%)

14 (67%)

 1-2/day

2 (4%)

0 (0%)

0 (0%)

2 (10%)

Smoking history

0.84

 Never

32 (62%)

8 (53%)

9 (56%)

15 (71%)

 Past

17 (33%)

6 (40%)

6 (38%)

5 (24%)

 Current

3 (6%)

1 (7%)

1 (6%)

1 (5%)

 Pack-year

0.0 (0.0, 9.3)

0.0 (0.0, 7.5)

0.0 (0.0, 11.3)

0.0 (0.0, 3.0)

0.48

Cancer treatment

 Trastuzumab relative dose intensity (%)*

102.6 (100.1, 106.5)

103.9 (101.0, 107.7)

103.1 (102.0, 106.6)

100.9 (98.8, 104.0)

0.14

 Anthracyclines

7 (13%)

2 (13%)

3 (19%)

2 (10%)

0.87

 Left radiotherapy

24 (46%)

8 (53%)

6 (38%)

10 (48%)

0.67